Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100

NCT ID: NCT03505567

Last Updated: 2018-09-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-04-21
• Study Completion Date: 2018-09-01

Brief Summary

This study is a prospective comparative study to gather pilot agreement and precision data in normal subjects, subjects with glaucoma, and subjects with retinal disease.

Conditions

Glaucoma; Retinal Disease; Healthy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Random Sequenced Interventions

Participants from three condition groups (normal, glaucoma, retinal disease) assigned two interventions (Kowa OCT Bi-μ and the Optovue iVue 100) under random sequence assignments.

Group Type: OTHER

KOWA OCT Bi-µ

Intervention Type: DEVICE

Non-contact, ultra-high resolution ophthalmic imaging system for fundus imaging and axial cross-sectional and three-dimensional imaging of retinal structures.

Optovue iVue 100

Intervention Type: DEVICE

U.S. Food and Drug Administration (FDA) cleared and commercially available Optovue iVue 100

Interventions

KOWA OCT Bi-µ

Non-contact, ultra-high resolution ophthalmic imaging system for fundus imaging and axial cross-sectional and three-dimensional imaging of retinal structures.

Intervention Type: DEVICE

Optovue iVue 100

U.S. Food and Drug Administration (FDA) cleared and commercially available Optovue iVue 100

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Subjects with normal eye examinations (without pathology other than cataract) in one or both eyes on the date of the study visit;
• Subjects with intraocular pressure (IOP) ≤ 21 mmHg in the normal eye(s) on the date of the study visit; and
• Subjects with current best-spectacle-corrected visual acuity (BSCVA) of 20/40 or better in the normal eye(s) on the date the study visit.

• Subjects who have been diagnosed with glaucoma in the glaucoma study eye(s), with optic nerve damage as evidenced by either of the following optic disc or retinal nerve fiber layer structural abnormalities observed via fundus exam during the study visit:

1. Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles with or without disc hemorrhage; or

2. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue;

• Subjects with a current BSCVA of 20/40 or better in the glaucoma study eye(s) on the date of the visit; and
• History of visual field defects within the previous two (2) months from the study visit or measured on the day of the study visit that is consistent with glaucomatous optic nerve damage based on at least one of the following findings:

1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level; and

2. Glaucoma hemi-field test "outside normal limits."

• Subjects with current IOP ≤ 21 mmHg in the retinal disease study eye(s) on the day of the study visit;
• Subjects with a current BSCVA of 20/400 or better in the retinal disease study eye(s) at the study visit; and
• Subjects diagnosed with retinal pathology including but not limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Cystoid Macular Edema, and others in the retinal disease study eye(s) as confirmed within the past six (6) months.

Exclusion Criteria

• Subjects unable to tolerate ophthalmic imaging;
• Subjects with ocular media not sufficiently clear to obtain acceptable OCT images;
• Subjects with any current ocular pathology other than cataract in the normal eye(s), as determined by self-report and/or investigator assessment at the study visit;
• Subjects with current narrow anterior chamber drainage angle in the normal eye(s), as determined by self-report and/or investigator assessment at the study visit; and
• Subjects with a history of leukemia, dementia or multiple sclerosis.

• Subjects unable to tolerate ophthalmic imaging;
• Subjects with ocular media not sufficiently clear to obtain acceptable OCT images;
• Subjects with at least one Humphrey Field Analyzer (HFA) visual field (24-2 SITA Standard, white on white) measured on the day of the study visit, or within the previous two (2) months from the study visit with unreliable results, defined as fixation losses > 20%, or false positives > 33%, or false negatives > 33% in the glaucoma study eye(s);
• Subjects with any current ocular pathology except glaucoma in the glaucoma study eye(s), as determined by self-report and/or investigator assessment on the day of the study visit; and
• Subjects with a history of leukemia, dementia or multiple sclerosis.

• Subjects unable to tolerate ophthalmic imaging;
• Subjects with ocular media not sufficiently clear to obtain acceptable OCT images;
• Subjects with glaucoma or any ocular pathology other than retinal pathology (e.g. cornea pathology) in the retinal disease study eye(s), as determined by self-report and/or investigator assessment at the study visit;
• Subjects with current narrow anterior chamber drainage angle in the retinal disease study eye(s), as determined by self-report and/or investigator assessment at the study visit; and
• Subjects with a history of leukemia, dementia or multiple sclerosis.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Kowa Research Institute, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David Hosford, MD, Ph.D

Role: STUDY_DIRECTOR

Kowa Research Institute, Inc.

Locations

Andover Eye Associates

Andover, Massachusetts, United States

Countries

United States

Other Identifiers

RT1-01US

Identifier Type: -

Identifier Source: org_study_id